Dipexium Pharmaceuticals
Date | Investors | Amount | Round |
---|---|---|---|
N/A | $2.7m | Early VC | |
N/A | $2.7m | Seed | |
N/A | $510k | Early VC | |
N/A | $930k | Early VC | |
N/A | $2.8m | Early VC | |
N/A | N/A | IPO | |
N/A | Acquisition | ||
Total Funding | €8.8m |
Recent News about Dipexium Pharmaceuticals
EditDipexium Pharmaceuticals specializes in the production and distribution of full spectrum CBD oil, targeting individuals seeking natural remedies for pain relief, stress, and anxiety. Operating within the health and wellness market, the company serves a diverse clientele including individuals with chronic pain, anxiety disorders, and those looking for general wellness solutions. Dipexium's business model revolves around direct-to-consumer sales through their online platform, ensuring accessibility and convenience for their customers. The company generates revenue by selling high-quality, organic, pesticide-free CBD oil products, which are cold-pressed using CO2 extraction methods to ensure maximum purity and potency. Their products are highly rated by customers for their effectiveness and fast-acting relief.
Keywords: CBD oil, pain relief, stress relief, anxiety relief, organic, pesticide-free, CO2 extraction, wellness, direct-to-consumer, high potency.